Alzheimer's patient has one. there's another hurdle. donanemab has potentially serious side effects. it can cause swelling and bleeding in the brain, so patients will need to be aware of the risks and be carefully monitored. but despite safety concerns, there will be huge demand for this new drug, which mike will continue to receive as long as it helps him. after decades of failed trials, the era of alzheimer's treatment is upon us. so important to so many families out there. we can speak now to bart de strooper, a professor in alzheimer's disease at university college london and director of u...